JNJ: Q4 & FY 2013 Results (Johnson and Johnson Ltd) - Jan 23, 2014 - Anticipated filing of TMC647055 + JNJ56914845 + simeprevir combo in EU for hep C infection between 2014 and 2017; Anticipated filing of TMC647055 + JNJ56914845 + simeprevir combo in US for hep C infection between 2014 and 2017
Anticipated EU regulatory • Anticipated NDA • Hepatitis C Virus
|